Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Operating Income
Mayne Pharma Group Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Operating Income
-AU$165.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Operating Income
-AU$10.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Operating Income
AU$204.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
102%
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Operating Income
-AU$18.3m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-28%
|
|
Probiotec Ltd
ASX:PBP
|
Operating Income
AU$20m
|
CAGR 3-Years
31%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Operating Income
-AU$26.4m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Operating Income?
Operating Income
-165.5m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Operating Income amounts to -165.5m AUD.
What is Mayne Pharma Group Ltd's Operating Income growth rate?
Operating Income CAGR 1Y
-196%
Over the last year, the Operating Income growth was -196%.